SCHEMBL6509102

SCHEMBL6509102

COCOc1ccc(C(C=O)c2cccnc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 5/20 0.38
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ADRB1 P08588 3/20 0.36
ADRB2 P07550 1/20 0.36
PDE4D Q08499 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP19A1 P11511 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 1/20 0.36
LMNA P02545 2/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498908 0.85 KMT2A (0.46) ALDH1A1POLBCYP3A4CYP19A1CYP2C19
SCHEMBL1515880 0.84 FFAR1 (0.40) ALDH1A1POLBKMT2AL3MBTL1
SCHEMBL9312935 0.82 PDE4D (0.40) ADRB3ALDH1A1TP53POLBTDP1
SCHEMBL7492214 0.81 MAPK1 (0.54) KMT2A
Ammonia Solution, Strong SCHEMBL8317322 0.80 TBXAS1 (0.44) CYP3A4CYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL8318114 0.80 SMN1; SMN2 (0.57) ADRB3ADRB1ADRB2CYP3A4CYP2D6
SCHEMBL8317319 0.77 KCNA5 (0.40) PDE4DCYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL6987746 0.77 TBXAS1 (0.37) ADRB3CYP19A1MAPTLMNASMN1; SMN2
SCHEMBL6505294 0.77 ALDH1A1 (0.42) ALDH1A1POLBCYP3A4CYP19A1LMNA
SCHEMBL8313802 0.77 FFAR1 (0.53) PDE4DLMNASMN1; SMN2KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 ADRB3 2198/4885ALDH1A1 3345/4885TP53 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.